Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
Key Highlights
- ➤Prime Medicine (PRME) launches $125.0 million underwritten common-stock offering
- ➤Underwriters receive 30-day option for up to an additional $18.75 million
- ➤Offering remains subject to market conditions, with no assurance of completion or final terms
- ➤Jefferies, TD Cowen, and Goldman Sachs serve as joint book-running managers
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. All of the shares of common stock in the proposed offering are to be sold by Prime Medicine. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Jefferies, TD Cowen and Goldman Sachs & Co. LLC are acting as joint book-running managers for the proposed offering. Oppenheimer & Co. and LifeSci Capital are acting as passive bookrunning managers for the proposed offering.
Get started
Create a free account to read the full story.